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Systemic sclerosis (SSc) is characterized by excessive fibrosis and obliterative vascular lesions.
Abnormal TGFb activation is implicated in the pathogenesis of SSc. Aberrant TGFb/Smad
signaling can be controlled by stabilization of microtubules with paclitaxel.
Methods and Findings
SSc and healthy human skin biopsies were incubated in the presence or absence of paclitaxel
followed by transplantation into severe combined immunodeficient mice. TGFb signaling,
fibrosis, and neovessel formation were evaluated by quantitative RT-PCR and immunohis-
tochemical staining. Paclitaxel markedly suppressed Smad2 and Smad3 phosphorylation and
collagen deposition in SSc grafts. As a result, the autonomous maintenance/reconstitution of
the SSc phenotype was prevented. Remarkably, SSc grafts showed a 2-fold increase in
neovessel formation relative to normal grafts, regardless of paclitaxel treatment. Angiogenesis
in SSc grafts was associated with a substantial increase in mouse PECAM-1 expression,
indicating the mouse origin of the neovascular cells.
Conclusion
Low-dose paclitaxel can significantly suppress TGFb/Smad activity and lessen fibrosis in SCID
mice. Transplantation of SSc skin into SCID mice elicits a strong angiogenesis—an effect not
affected by paclitaxel. Although prolonged chemotherapy with paclitaxel at higher doses is
associated with pro-fibrotic and anti-angiogenic changes, the findings described here indicate
that low-dose paclitaxel may have therapeutic benefits for SSc via modulating TGFb signaling.
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Systemic sclerosis (SSc) is an autoimmune disease charac-
terized by excessive deposition of extracellular matrix (ECM)
proteins and obliterative vascular lesions in the skin and
internal organs [1]. Although the causative factors of this
disease remain to be characterized, the main pathobiological
features of SSc comprise three interactive components:
autoimmune attack, vascular damage, and a lesion in
ﬁbroblasts [2,3]. The ﬁbrotic process consists of massive
deposition of connective tissue, mostly collagens, which is
frequently responsible for the failure of many organs in
patients with SSc. Consequently, an array of antiﬁbrotic
agents has been developed to: (1) reduce synthesis, excretion,
or polymerization of collagen ﬁbrils; (2) enhance collagenase
activity; and (3) neutralize cytokines capable of stimulating
collagen synthesis, such as TGFb (transforming growth factor-
beta), interleukin-4, and interleukin-6. To date, several of
these antiﬁbrotic agents have been tested in clinical trials [4].
These include D-penicillamine, colchicine, interferon gamma,
and relaxin. Unfortunately, none of these medicines have any
proven efﬁcacy in retarding the ﬁbrotic process [5].
TGFb is a multifunctional regulatory cytokine that is
involved in a large number of cellular activities. TGFb
induces matrix accumulation and tissue ﬁbrosis associated
with SSc [4]. In addition, TGFb promotes endothelial cell
apoptosis (a property that may be ampliﬁed by the presence
of anti-endothelial cell autoantibodies found in SSc), and
inhibits smooth muscle cell apoptosis. It also regulates T
lymphocyte–mediated immune reactions [6]. Thus, TGFb is
believed to play a central role in the pathogenesis of SSc by
activating tissue ﬁbroblasts directly or indirectly through
endothelial cells, by regulating lymphocyte function, and by
affecting endothelial and smooth muscle cell survival and
thrombus formation. Therefore, it is conceivable that
inhibition of the aberrant TGFb signaling may be a promising
therapeutic strategy for SSc.
TGFb initiates its diverse cellular responses by binding to
and activating speciﬁc cell-surface receptors that have
intrinsic serine/threonine kinase activity. The activated TGFb
receptorsstimulatethephosphorylationofreceptor-regulated
Smad2 and Smad3 proteins (R-Smads), which in turn form
complexes with Smad4 that accumulate in the nucleus and
regulate the transcription of target genes. Inhibitory Smad7
acts in an opposing manner to the R-Smads, inhibiting TGFb
signaling [7]. We have previously demonstrated that endoge-
nous Smad-2,  3, and  4 bind microtubules (MTs) in several
cell lines, and the binding provides a negative regulatory
mechanism to control TGFb activity. Disruption of the MT
network by chemical agents, such as nocodazole and colchi-
cine, leads to ligand-independent Smad nuclear accumulation
and transcription of TGFb-responsive genes, and increases
TGFb-induced Smad activity [8]. We have also found that
inhibitory Smad7 is selectively decreased, and we and others
have shown that R-Smad3 is increased, in SSc skin ﬁbroblasts,
resulting in uncontrolled TGFb activity that may be, at least in
part, responsible for the aberrant ECM deposition observed in
SSc [9]. Indeed, in a hybrid human–severe combined immu-
nodeﬁcient (SCID) mouse skin xenotransplant model, we were
able to maintain/reconstitute the SSc phenotype using skin
biopsies from SSc patients, indicating that the altered balance
between inhibitory Smad7 and R-Smads, due to Smad7
deﬁciency and Smad3 up-regulation, may represent an
intrinsic and persistent defect in tissue ﬁbroblasts that can
maintain or even induce SSc lesions autonomously in the
absence of altered circulatory or systemic factors [9]. The aim
ofthisstudywastodetermineifMTstabilizationwithlow-dose
paclitaxel could inhibit TGFb/Smad signaling, ameliorating
the ﬁbrotic changes associated with SSc.
Methods
Participant Characteristics
Skin biopsy (6-mm punch) was obtained in an area above
the elbow considered to have grossly intact skin thickness as
determined by clinical palpation of patients with SSc and in
the same location of control participants. Thirty-two
patients, of whom 26 were female and 6 were male, aged
38–64 y of age (average 48 y) with diffuse cutaneous SSc were
studied. The median duration of skin disease was 5.5 y (2–10
y). Concomitant treatment of SSc patients included the
immunosuppressant mycophenolate mofetil, angiotensin-
converting enzyme inhibitors, calcium channel blockers,
and proton-pump inhibitors. These patients were recruited
from the Johns Hopkins University Scleroderma Center. All
patients met the American College of Rheumatology criteria
for the diagnosis of SSc [10]. Patients with overlap syndromes
(e.g., lupus) were excluded. Twelve normal participants,
including nine women and three men with an average age
of 44 y (range 33–58 y) were also analyzed. All patients and
volunteers gave their informed consent, and the study was
approved by the Johns Hopkins University Human Subjects
Institutional Review Board Committee.
Skin Transplantation
SCID mice (C.B-17/lcrHsd-scid) were purchased from
Jackson Laboratory (Bar Harbor, Maine, United States). Mice
aged 6–8 wk and weighing 18–22 g were used for trans-
plantation. Brieﬂy, the skin biopsy patch was trimmed into an
oval shape depleted of fat tissue, and placed in 2 mM
paclitaxel (Taxol; Sigma, St. Louis, Missouri, United States) or
in PBS for 30 min at 4 8C. The tissue was rinsed with PBS just
before transplantation. On the dorsolateral surface of the
recipient SCID mouse, an oval graft bed approximately 6 mm
in diameter was created to ﬁt the graft, leaving the deep fascia
layer intact. The trimmed skin patch was transplanted onto
the graft bed by suturing the skin patch into the defect with
8–0 suture around the margin of the patch. A total of 25
transplants, including 17 SSc grafts and eight normal grafts,
were included in the study (Table 1). The grafts, together with
a small ring of the native skin, were harvested at 30 d
following transplantation. Nineteen non-transplanted biopsy
samples (15 SSc and four normal) were included as non-
surgical controls. Upon sacriﬁce, the underside of the skin
was photographed for angiogenesis study, and the tissue was
then divided into two segments: One segment was ﬁxed in
10% neutral buffered formalin and embedded in parafﬁn,
and the other segment was stored in RNAlater (Ambion,
Austin, Texas, United States) for RNA expression studies. All
animals were cared for in compliance with the ‘‘Principles of
Laboratory Animal Care and the Guide for the Care and Use
of Laboratory Animals,’’ prepared by the Institute of
Laboratory Animal Resources and published by the National
Institutes of Health (NO86 to 23, revised 1985).
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SSc and normal specimens were processed by 10%
formalin-ﬁxation and parafﬁn-embedding. Immunohisto-
chemistry (IHC) for Smad2, Smad3 (Santa Cruz Biotechnol-
ogy, Santa Cruz, California, United States), phospho-Smad2
(Upstate Biotechnology, Lake Placid, New York, United
States), phospho-Smad3 (a generous gift from Dr. Peter ten
Dijke, Leiden University, Leiden, The Netherlands), collagen-
1 (Santa Cruz Biotechnology), and PAI-1 (American Diag-
nostica, Greenwich, Connecticut, United States) was per-
formed using Vector’s ABC kits (Vector Laboratories,
Burlingame, California, United States) on 3-lm consecutive
serial sections. Brieﬂy, after deparafﬁnization, slides were
quenched in 3% H2O2 for 10 min to block endogenous
peroxidase and washed in PBS. Sections were incubated with
the primary antibody for 1 h and then with biotinylated
secondary antibody followed by ABC reagents. Color devel-
opment was achieved by incubating diaminobenzidine (DAB)
as a substrate. Slides were counterstained with Mayer’s
hematoxylin. Preincubation of the primary antibody with
speciﬁc blocking peptides or substitution of the primary
antibody with an irrelevant IgG served as negative controls.
Smad2- and Smad3-positive cells were counted in at least six
high-power ﬁelds in each sample by two independent
observers (CMD and XL). A minimum of 500 cells was
counted. Percent positive cells were calculated as the number
of positive cells/total number of cells3100. Cells positive for
phospho-Smad2 and phospho-Smad3 were counted in a
similar fashion. Among the Smad2- and Smad3-positive cells,
the percentage of those stained for phospho-Smad2 and
phospho-Smad3 was calculated as the number of phospho-
Smad2– and phospho-Smad3–positive cells/the number of
cells positive for Smad2 and Smad3, respectively, 3 100.
Sections in series with IHC were stained with H & E
(hematoxylin/eosin), and Verhoeff’s van Gieson elastin and
Mason trichrome (VVM). Each section was examined for the
presence, extent, and distribution of collagen, elastic ﬁbers,
and other matrix proteins.
Angiogenesis Assessment
The number of microvessels was counted from three to ﬁve
randomly selected high-power ﬁelds (403 magniﬁcation) in
histology slides stained with H & E. Neovessel formation was
also evaluated macroscopically by counting the number of
vessels on the underside of the grafts and skin biopsies in a 6-
mm ﬁeld—the entire graft. Angiogenic activity was compared
among different groups, including SSc skin biopsy, SSc grafts,
normal skin biopsy, and normal skin grafts.
TaqMan Real-Time Reverse Transcription-PCR
RNA was isolated from the skin using RNeasy Mini kit
(Quiagen, Chatsworth, California, United States). One lg
total RNA was used for the synthesis of ﬁrst strand cDNA
using the SUPERSCRIPT Preampliﬁcation System (Life
Technologies, Rockville, Maryland, United States). PCR was
optimized for the quantitation of alpha2(I) collagen (COL1A2;
mouse and human share the same sequence), human PECAM-
1 (platelet endothelial cell adhesion molecule-1), and mouse
PECAM-1 with speciﬁc primers and probes. A sequence
detector (ABI Prism 7700, PE Applied Biosystems, Foster City,
California, United States) was used to measure the ampliﬁed
product in direct proportion to the increase in ﬂuorescence
emission continuously during the PCR ampliﬁcation. For
each sample, a threshold cycle (Ct) value was calculated from
each ampliﬁcation plot, representing the PCR cycle number
at which the ﬂuorescence was detectable above an arbitrary
threshold. To normalize Ct of the target gene copies to 18S
rRNA, DCt was calculated as Ct (target)  Ct (18S rRNA). For
each sample, the level of COL1A2, human PECAM-1, and
mouse PECAM-1 was calculated as 2
 DCt. Each sample was
tested in triplicate and repeated twice.
Statistical Analysis
Data are presented as mean 6 SEM. Analysis of variance was
performed to compare differences among different groups. A
p-value , 0.05 was considered statistically signiﬁcant.
Results
Paclitaxel Inhibits TGFb/Smad Signaling and Collagen
Deposition in SSc Grafts
We demonstrated previously that because of the Smad7
deﬁciency and increased Smad3 expression in SSc ﬁbroblasts,
transplantation of SSc skin retained the SSc phenotype in
SCID mice, indicating that the altered balance between
positive and inhibitory Smads may represent an intrinsic
defect in tissue ﬁbroblasts that can maintain or even induce
SSc lesions autonomously in the absence of altered circu-
latory or systemic factors [9]. Since MT instability enhances
TGFb/Smad signaling pathway [8], we reasoned that stabiliza-
tion of MTs with paclitaxel might dampen the exacerbated
TGFb signaling in the SSC grafts and prevent the main-
tenance/reconstitution of SSc phenotype. IHC using anti-
phospho-Smad2 antibody revealed enhanced Smad2 phos-
phorylation, a marker for TGFb signaling, in SSc tissue,
relative to normal skin specimens (87% 6 11% versus 23% 6
15%, p , 0.01), when both pre- and post-transplant tissues
were analyzed together, whereas the level of total Smad2
remained comparable between normal versus SSc skin tissue.
Remarkably, pre-transplant incubation of SSc skin with
paclitaxel substantially suppressed the level of Smad2
phosphorylation, approaching that of normal grafts (28% 6
19% versus 21% 6 13%, p . 0.05; (Figure1A–1F). Minimal, if
any, effects of paclitaxel on Smad2 activity in normal skin
grafts were detected (normal grafts þ paclitaxel, 26% 6 18%
versus normal grafts, 21% 6 13%, p . 0.05). Furthermore,
the level of total Smad2 and Smad7 (data not shown)
remained unchanged.
Table 1. The Summary of Skin Samples Used in the Study
Category Group Number
Non-transplantation (n ¼ 19) SSc skin 15
Normal skin 4
Xenotransplantation (n ¼ 25) SSc skin grafts treated with paclitaxel 12
SSc skin grafts—sham treatment
(0.9% saline)
5
Normal skin graft treated with paclitaxel 4
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in SSc specimens compared to normal skin tissue (83% 6
11% versus 20% 6 15%, p , 0.01). In addition, the level of
total Smad3 was increased in SSc versus normal skin tissue
(81.5% 6 10% versus 55% 6 21%, p , 0.01)—an observation
that is consistent with our previous study. Importantly, pre-
transplant incubation of SSc skin substantially suppressed the
level of Smad3 phosphorylation to that of normal grafts (27%
6 14% versus 24% 6 13%, p . 0.05). Furthermore, the
expression level of total Smad3 was also downregulated by
paclitaxel treatment in SSc (81.5% 6 10% versus 57. 5% 6
12%, p ¼ 0.05) (Figure S1A–S1F). There was no detectable
effect of paclitaxel on Smad3 activation in normal skin grafts
(30% 6 16% versus 25% 6 11%, p . 0.05). These ﬁndings
indicate that preincubation of SSc skin with paclitaxel can
effectively offset Smad7 deﬁciency and Smad3 up-regulation–
induced augmented TGFb signaling in SSc skin grafts, without
affecting the total Smad2 and Smad7 expression level.
Moreover, when TGFb signaling is not perturbed in normal
skin grafts, paclitaxel does not exert detectable effects.
The progressive accumulation of ECM in the skin and
internal organs is a hallmark of SSc, of which collagen type I
is the major constituent. Indeed, collagen type I metabolites
have been used as markers to evaluate disease activity in SSc
[11]. To examine whether paclitaxel treatment affected
collagen deposition in SSc skin grafts, we performed
quantitative TaqMan real-time reverse transcription-PCR
(TRT-PCR) for COL1A2. Instructively, the expression of
COL1A2—a gene whose promoter contains multiple Smad-
binding elements (SBE)—was reduced by 4.5-fold (p , 0.01)
with paclitaxel treatment in SSC grafts, reaching a level that
approximated COL1A2 mRNA expression in normal skin
grafts. By contrast, paclitaxel had hardly any effects on
COL1A2 mRNA expression in normal skin grafts (Figure 2).
To conﬁrm the TRT-PCR ﬁndings, we performed histo-
logical VVM staining to evaluate total collagen deposition
and IHC to examine collagen-1 expression level. As shown in
Figure 3, there was extensive deposition of total collagen and
other ECM proteins, including elastic ﬁbers, in the entire
dermis of SSc grafts, which was markedly reduced with
paclitaxel treatment. Strong, intense collagen-1 staining was
demonstrated in untreated SSc grafts, relative to much
weaker staining in paclitaxel-treated SSc tissue, which was
comparable to normal skin grafts treated with and without
paclitaxel (Figure 3). These data indicate that low-dose
paclitaxel prevents the maintenance/reconstitution of the
SSc phenotype in SCID mice, and this effect may be mediated
by stabilizing MT-Smad complex and subsequent inhibition
of TGFb/Smad signaling.
Paclitaxel Does Not Affect the Enhanced Local
Angiogenesis in SSc Skin Grafts
SSc skin lesions are characterized by obliterative micro-
vascular lesions and decreased capillary density, suggesting
Figure 1. Paclitaxel Treatment Suppresses Smad2 Phosphorylation
Strong nuclear staining for phospho-Smad2 (A) and total Smad2 (B) is observed in an SSc skin graft. Smad2 phosphorylation (C) is rare in normal graft,
which expresses abundant Smad2 (D). Smad2 phosphorylation is suppressed with paclitaxel (Taxol) treatment (E), without affecting total Smad2 (F) in
SSc skin graft. Tx, transplantation.
DOI: 10.1371/journal.pmed.0020354.g001
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angiogenic response [12]. Three basic mechanisms could
account for the defective vascular repair in SSc: (1) lack of
signals produced by the skin to recruit progenitor cells from
the bone marrow, (2) appropriate skin recruitment signals
but failure of the bone marrow to mount an adequate repair
process, and (3) appropriate skin recruitment signals and
adequate bone marrow endothelial progenitor cell (EPC)
supply but excessive destruction of EPCs upon their
mobilization by immune system. To determine if the
defective angiogenic response might be related to lack of
signals produced by the skin to recruit progenitor cells from
the bone marrow and whether paclitaxel would adversely
affect the angiogenic process in SCID mice, we examined
neovessel formation following SSc and normal skin trans-
plantation. The EPC supply from the mouse bone marrow is
assumed to be nonlimiting. Macroscopic examination of the
underside of the 6-mm skin grafts revealed more pronounced
angiogenesis in SSc grafts than normal skin transplants
(Figure 4A–4D). There were on average 30 vessels in the SSc
graft in three high-power ﬁelds (403), as compared with 15
vessels in normal skin grafts (p , 0.01) (Figure 4E). To further
conﬁrm these ﬁndings and determine the origin of the
neovascular cells, we performed TRT-PCR for human and
mouse PECAM-1, an endothelial cell marker. If bone marrow
failure and/or autoimmunity-mediated EPC destruction, but
not secretion of mobilizing factors by the skin, represented
the major bottleneck for a defect repair process in SSc, an
aggressive angiogenic response with mouse progenitor cells
and, therefore, increased mouse PECAM-1, in the SSc grafts
would be expected. As shown in Figure 4F, mouse PECAM-1
was almost undetectable in SSc and normal skin biopsies
before transplantation, reﬂecting the speciﬁcity of the
primers and probe for the mouse gene. Substantial increase
in mouse PECAM-1 mRNA expression was observed in SSc
and normal skin grafts. The amplitude of the increase in
mouse PECAM-1, however, was signiﬁcantly greater in SSc
than in normal grafts (p , 0.01). Human PECAM-1 was
expressed in much lower levels in SSc than in normal skin
tissue (p , 0.01) before transplantation, indicative of vascular
deﬁciency in SSc. The level of human PECAM-1 did not
change signiﬁcantly before and after transplantation (Figure
4G). Collectively, these data indicate that the neovascular cells
are of recipient mouse origin and that exhaustion of EPC
supply from the patient’s bone marrow and/or autoimmunity-
mediated targeting and destruction of EPCs after mobiliza-
tion may contribute to the vascular lesion associated with SSc.
The putative activity of paclitaxel to induce endothelial cell
or EPC apoptosis and/or to inhibit the proliferation of these
cells with subsequent blockade of angiogenesis represented a
potential untoward side effect for the use of paclitaxel in the
treatment of SSc. To exclude this possibility, we compared
the number of vessels in SSc and normal skin grafts treated
with and without paclitaxel. As shown in Figure 4A–4E,
treatment with paclitaxel did not adversely affect the
angiogenic process. A similar increase in neovessel formation
was observed in paclitaxel-treated versus nontreated SSc
Figure 2. Paclitaxel Decreases COLA2 mRNA Expression in SSc Grafts
TRT-PCR analysis shows that the expression of COL1A2 is reduced 4.5-fold
with paclitaxel (Taxol) treatment in SSC grafts, reaching a level equivalent
to that of normal skin grafts. By contrast, paclitaxel has no effects on
COL1A2 expression in normal skin grafts.
DOI: 10.1371/journal.pmed.0020354.g002
Figure 3. Paclitaxel Decreases Collagen Deposition in SSc Grafts
VVM staining shows abundant, thick collagen bundles in the SSc graft (A). The amount of collagen is markedly reduced, and the collagen fibers become
finer with paclitaxel (Taxol) treatment (B), comparable to that seen in the normal skin graft (C). Similarly, IHC staining demonstrates intense collagen-1
staining in the SSc graft (D), which is substantially decreased with paclitaxel treatment (E) to a level similar to that seen in the normal skin graft (F).
DOI: 10.1371/journal.pmed.0020354.g003
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from the same patients. Furthermore, paclitaxel incubation
had little, if any, effect on the expression level of PECAM-1
mRNA, in particular mouse PECAM-1, in SSc and normal skin
grafts (Figure 4F and 4G). These ﬁndings support the notion
that low-dose paclitaxel can be used to modulate TGFb/Smad
signaling and treat the ﬁbrotic lesion, without adversely
affecting the vascular component of SSc pathobiology.
Discussion
In the present study, we found that the autonomous
maintenance/reconstitution of the SSc phenotype in the
hybrid SCID mouse transplant model was substantially
prevented by pre-transplant incubation of the SSc skin with
2 mM paclitaxel (taxol), an MT-stabilizing agent. Further-
more, SSc grafts showed a 2-fold increase in neovessel
formation, as compared with normal skin grafts, regardless
of paclitaxel treatment. The angiogenic process in SSc grafts
was associated with a substantial increase in mouse, but not
human, PECAM-1 expression, pointing the origin of the
neovascular cells to the recipient mice, perhaps the bone
marrow. The angiogenesis data suggest that the skin of
patients with SSc has preserved ability to trigger and support
an angiogenic response. Collectively, these ﬁndings indicate
that low-dose paclitaxel may potentially help keep in check
the ﬁbrotic process associated with SSc, without adversely
affecting the vascular component of the disease.
Members of the TGFb superfamily play a central role in
ﬁbrosis, contributing to the inﬂux and activation of inﬂam-
matory cells and ﬁbroblasts and their subsequent elaboration
of ECM [4]. TGFb propagates its signal mainly via a signal
transduction network involving receptor serine/threonine
kinases at the cell surface and their substrates, the Smad
proteins. Upon phosphorylation and oligomerization, R-
Smads move into the nucleus to regulate transcription of
target genes [7]. Recent ﬁndings indicate that the aberrant
ECM synthesis by cultured SSc ﬁbroblasts is due, at least in
part, to the constitutively enhanced activation of the TGFb
signaling, which may result from the elevated levels of TGFb
receptor type I, inappropriate overexpression/activation of
Smad2 and Smad3, and/or decreased Smad7 expression.
Indeed, evidence obtained from Smad3-deﬁcient mice shows
that TGFb-induced pro-ﬁbrotic activities are mainly medi-
ated by Smad3 [13]. Smad3-deﬁcient inﬂammatory cells and
ﬁbroblasts do not respond to the chemotactic effects of TGFb
and do not auto-activate TGFb [14,15]. Furthermore, Smad3-
deﬁcient mice are resistant to radiation-induced cutaneous
ﬁbrosis, bleomycin-induced pulmonary ﬁbrosis, carbon tetra-
chloride–induced hepatic ﬁbrosis, and glomerular ﬁbrosis
induced by type 1 diabetes caused by streptozotocin [16,17].
We have demonstrated that Smad7, the inhibitory Smad
speciﬁc for TGFb signaling, is selectively decreased, whereas
Smad3 expression is increased in SSc ﬁbroblasts. TGFb
signaling events, including phosphorylation of Smad2 and
Smad3 and transcription of PAI-1 gene, are increased in SSc
ﬁbroblasts, relative to normal ﬁbroblasts. Importantly, the
imbalance between Smad7 and Smad3 itself can maintain or
Figure 4. SSc Skin Grafting Stimulates Angiogenesis in SCID Mice
Macroscopic analysis of the vessels in the underside of normal (A and B) and SSc (C and D) skin grafts reveals more pronounced angiogenesis in SSc
grafts; paclitaxel (Taxol) treatment has no effect on angiogenesis at the macroscopic level (B and D versus A and C). Microscopic analysis shows that the
number of vessels in three high-power fields of the SSc grafts is greater than that of normal skin grafts; paclitaxel has no effect on angiogenesis at the
microscopic level (E). TRT-PCR for mouse PECAM-1 demonstrates a substantial increase in mouse PECAM-1 mRNA expression in SSc and normal skin
grafts regardless of paclitaxel treatment; the amplitude of the increase is significantly greater in SSc than in normal skin grafts (F). Human PECAM-1 is
expressed in much lower levels in SSc than in normal skin tissues, indicative of vascular deficiency in SSc; the lack of difference in the expression level of
human PECAM-1 in SSc and normal skin tissues before and after transplantation indicates that the neovascular cells are derived from the recipients (G).
DOI: 10.1371/journal.pmed.0020354.g004
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have previously shown that MTs serve as a negative regulator
for TGFb/Smad signaling by forming a complex with
endogenous Smad2, Smad3, and Smad4, sequestering the R-
Smads away from the TGFb receptor in several cell types [8].
Stabilization of MTs by low-dose paclitaxel can dampen to a
normal level the exacerbated TGFb signaling due to MT
instability and block TGFb-induced inhibition of myogenesis
in C2C12 myoblasts [18]. In the present study, we provide
evidence indicating that transient incubation of SSc skin with
paclitaxel before transplantation into SCID mice substan-
tially suppressed the phosphorylation of Smad2 and Smad3,
two homologous Smad proteins that transduce signals from
TGFb and activin. Remarkably, paclitaxel treatment efﬁ-
ciently blocks the autonomous reconstitution and mainte-
nance of the SSc phenotype in SCID mice. These data are
consistent with our previous observations, supporting the
notion that TGFb/Smad signaling is regulated by the dynamic
stability of MTs, which is sensitive to low-dose MT stabilizing
agents, like paclitaxel.
Prolonged chemotherapeutic treatment with paclitaxel has
been associated with scleroderma-like changes, albeit in only
a small fraction of patients. It is noteworthy that the anti-
tumor effect of paclitaxel is mediated via the inhibition of
cell proliferation and requires a much higher dosage. The
inhibition of TGFb/Smad signaling, however, can be achieved
with very-low-dose paclitaxel. We and others have demon-
strated that low-dose paclitaxel had minimal, if any,
detectable effects on cell proliferation and other cellular
activities, including ﬁbrosis. Intriguingly, low-dose paclitaxel
has been shown to inhibit collagen-induced arthritis and
other autoimmune disorders in various animal models[19,20].
The low-dose paclitaxel treatment in our human–SCID
mouse skin transplant model resulted in marked inhibition
of TGFb/Smad signaling, as evidenced by the decreased
phosphorylation of Smad2 and Smad3, and lessened ﬁbrosis.
Our data indicate that under our experimental conditions in
the SCID mouse, low-dose paclitaxel does not induce
scleroderma skin changes. This does not, however, refute
the potential linkage between higher doses of paclitaxel used
for cancer therapy in humans and skin ﬁbrosis.
The structural and functional vascular and microvascular
abnormalities, including Raynaud’s phenomenon, represent
one of the most important pathological features of SSc [12].
Indeed, microvascular damage and consequent loss of blood
supply is found in all involved organs and leads to under-
perfusion and chronic ischemia, which may play an impor-
tant role in organ dysfunction and even in the pathogenesis
of in SSc. The ﬁbrotic changes may represent a default
pathway resulting from vascular failure. Endothelial apopto-
sis caused by viral infection, immune reactions to viral or
environmental factors, reperfusion injury, or anti-endothelial
antibodies, is considered a precipitating event in the genesis
of vascular lesions in SSc [21]. Recent evidence, however,
indicates that vascular repair, particularly that mediated via
adult stem cells/EPCs from the bone marrow, plays an
important role in maintaining vascular homeostasis and
angiogenesis in a variety of disease states [22,23]. It is
hypothesized that the vessel wall can deal fairly well with
multiple circulating and local noxious stimuli as long as the
bone marrow–derived repair capacity remains intact [24].
Indeed, many autoimmune processes might target the repair
pathways that are needed to maintain the homeostasis of
involved tissues [25]. Adequate vascular repair entails
adequate supply of competent progenitor cells in, and their
efﬁcient mobilization from the bone marrow, as well as the
effective homing to, and subsequent differentiation of these
progenitor cells within the vessel wall. Any dysregulation in
these processes can tilt the balance of vascular repair and
injury in favor of injury and vascular lesion formation. It was
postulated that the inadequate angiogenic response in SSc
was due to reduced expression of angiogenic factors, such as
vascular endothelial growth factor (VEGF), and their recep-
tors. It was recently shown, however, that both VEGF and its
receptors (VEGFR1 and VEGFR2) were up-regulated in SSc
skin specimens compared with healthy controls [26]. In
addition, VEGF protein was signiﬁcantly increased in blood
samples from patients with SSc, reaching levels observed in
patients with numerous malignant diseases [27]. Thus, there
appears to exist a proper, if not increased, activation of the
VEGF/VEGF-receptor axis—key to EPC mobilization—in
patients with SSc [26]. One could not, however, rule out the
possibility that other, yet to be identiﬁed, factors might be
missing from the skin and blood of SSc patients, factors that
are required to mount and support a successful angiogenic
response.
The human skin–SCID mouse transplantation model
provides a remarkable opportunity to determine whether
lack of signals from the skin of SSc patients to recruit EPCs
from the bone marrow might play a role in the vascular lesion
formation in SSc, since the bone marrow of the SCID mice is
considered intact in terms of EPC supply and there is an
absence of immune-mediated destruction of EPCs. Extensive
analysis of vascular formation following SSc and normal skin
transplantation both at microscopic and macroscopic levels
revealed a robust angiogenic response in the SSc grafts, at
least twice that seen in normal skin grafts. TRT-PCR for
human and mouse PECAM-1 demonstrated a substantial
increase in mouse PECAM-1 mRNA expression in SSc and
normal skin grafts. Furthermore, the amplitude of the
increase in mouse PECAM-1 was signiﬁcantly greater in SSc
than in normal grafts. In contrast, human PECAM-1 was
expressed in much lower levels in SSc than in normal skin
tissues before transplantation, indicative of vascular deﬁ-
ciency in SSc, and the expression level of human PECAM-1
did not change before and after transplantation in SSc and
normal skin tissues, indicating that the neovascular cells are
derived from the mouse recipients rather than the human
donors. These data indicate that the signals from SSc skin, if
anything, are stronger in stimulating the mobilization of
EPCs from the bone marrow. Moreover, the robust angio-
genic activity observed in SSC relative to normal grafts argues
against the possibility that the angiogenic response in the
SCID mouse is solely due to a wound-healing effect in
response to grafting procedures.
It remains to be determined, however, if the EPC supply in
the bone marrow or autoimmunity-induced targeting and
destruction of EPCs after their mobilization or both serve as
the culprit in undermining the vascular repair process,
contributing to vascular lesion formation in SSc. Using an
animal model of atherosclerosis, we have demonstrated that
exhaustion of selected progenitor cell populations, including
EPCs and their supporting cells, a process that is accelerated
by risk factors, can lead to the inability of the bone marrow to
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the initiation and progression of atherosclerotic vascular
lesion formation [22,28]. Circulating EPCs and CD34
þ/KDR
þ
precursor cells were reduced in patients with atherosclerotic
coronary artery disease. The reduction of these cells
represented signiﬁcant risk factors for atherosclerosis, even
after adjusting for most classic risk factors, including age, sex,
hypertension, diabetes, smoking, family history, and low-
density lipoprotein cholesterol levels. Furthermore, factors
that reduce cardiovascular risk, such as statins or exercise,
elevate EPC levels, which contribute to enhanced endothelial
repair. Hence, a reduced circulating EPC level has been
proposed as a signiﬁcant risk factor for cardiovascular
disease. There is conﬂicting evidence regarding the level of
circulating EPCs in SSc patients. Speciﬁcally, Kuwana et al.
[25] showed that the levels of circulating EPCs, deﬁned by the
expression of CD34, CD133, and VEGFR2, were decreased in
SSc patients. By contrast, Del Papa et al. [29] found that
circulating EPCs—cells positive for CD34 and CD133—were
increased in SSc patients, particularly in the early stages of
the disease. Although the discrepancy between these studies
might be due to the differing deﬁnitions of EPCs and
different disease stages of SSc patients, it underscores the
idea that further investigation is warranted in delineating the
relative contribution of inadequate bone marrow EPC supply
and excessive destruction of circulating EPCs to the
imbalance between vascular injury and repair in SSc.
The established mechanism that confers the antitumor
effects of paclitaxel relates to its antiproliferative and
antiangiogenic activity when used at large doses and for a
prolonged period of time [30]. Indeed, the putative anti-
angiogenic effect of paclitaxel represented our primary
concern for its use in the treatment of SSc. Remarkably,
when paclitaxel- and sham-treated SSc and normal grafts
were analyzed for their angiogenic response at microscopic
and macroscopic levels, similar numbers of vessels were
observed, indicating that low-dose paclitaxel does not affect
neovessel formation that is likely mediated via EPCs recruited
from the bone marrow.
In conclusion, we have demonstrated that SSc skin treated
with low-dose paclitaxel can signiﬁcantly suppress the
exacerbated TGFb/Smad activity of SSc skin and lessen the
ﬁbrotic changes upon transplantation into SCID mice. We
have found that transplantation of SSc skin into SCID mice
elicits effective angiogenesis—an effect that is signiﬁcantly
stronger than with normal skin grafting. Importantly, the
neovascular cells are almost exclusively derived from the
recipients, perhaps originating from the mouse bone marrow.
These observations should shed light on SSc disease patho-
genesis and provide evidence for the development of novel
therapeutic strategies. The fact that low-dose paclitaxel
suppresses ﬁbrosis without dysregulating angiogenesis sug-
gests that ﬁbrosis might be the result of a ‘‘default’’ pathway
that develops autonomy once the SSc tissue becomes
depleted of blood vessels.
Supporting Information
Figure S1. Paclitaxel Treatment Suppresses Smad3 Phosphorylation
Strong nuclear staining for phospho-Smad3 (A) and total Smad3 (B) is
observed in an SSc skin graft. Smad3 phosphorylation (C) is rare in
normal graft, which also expresses a low level of total Smad3 (D).
Smad3 phosphorylation and perhaps total Smad 3 are suppressed
with paclitaxel (Taxol) treatment in SSc (E and F).
Found at DOI: 10.1371/journal.pmed.0020354.sg001 (9.5 MB TIF).
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Patient Summary
Background Systemic sclerosis or scleroderma (SSc) is the name for a
group of progressive diseases, all of which involve the abnormal growth
of connective tissue. SSc is triggered when the body’s immune system
turns against the body, causing abnormal production of collagen that
can be limited to the skin or extend to the blood vessels and internal
organs.
Why Was This Study Done? Various genes have been suggested as
being involved in the production of collagen. One of the key genes in
this pathway, and in SSc, is TGFb, which affects the activity of a number
of other genes. A part of a cell’s internal structure, known as
microtubules, affects TGFb activity. Previous work has shown that
microtubules can be affected by drugs, such as the one in this study,
paclitaxel, which stabilizes the microtubules.
What Did the Researchers Do and Find? They looked at the effect of
paclitaxel on human skin samples that had been taken from people with
SSc, or from people with normal skin, and then transplanted into mice.
This transplantation is a good way of studying the effects of drugs in this
disease without having to test them directly on people. The researchers
found that paclitaxel affected the activity of TGFb and the related genes,
and ultimately decreased the amount of collagen that would usually be
found in the skin of people with SSc.
What Do These Findings Mean? These findings suggest that paclitaxel
would be worth investigating further as a useful drug in the treatment of
people with SSc. One concern, however, is that in people who have been
treated with high doses of this drug for other conditions, such as some
types of cancer, the opposite effect of that shown here has been found:
increased collagen has been produced. Therefore, before it can be
certain that this drug is safe to use, further work will need to be done to
determine what the different effects of the drug are at high and low
doses, and what a safe dose is in humans.
Where Can I Get More Information Online? MedlinePlus has many
links to pages of information on SSc:
http://www.nlm.nih.gov/medlineplus/scleroderma.html
The Scleroderma Foundation is a non-profit organization based in the
United States that provides information on scleroderma for patients, and
supports research:
http://www.scleroderma.org/
The Scleroderma Research Foundation, which helped support this work:
http://www.srfcure.org/
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